Patents by Inventor Luis F. Parada

Luis F. Parada has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUBSTITUTED BENZIMIDAZOLIUM, PYRIDO-IMIDAZOLIUM, OR PYRAZINO-IMIDAZOLIUM COMPOUNDS AS CHEMOTHERAPEUTICS
    Publication number: 20180354909
    Abstract: Provided herein are compounds of the formula:(I) wherein: R1, R2, R3, R4, R5, X, A1, A2, A3, and A4 are as defined herein. In some aspects, these compounds may be used to treat cancer and other hyperproliferative disease. In some aspects, compositions, methods of treatment, and methods of synthesis are also provided herein.
    Type: Application
    Filed: December 9, 2016
    Publication date: December 13, 2018
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Jef DE BRABANDER, Luis F. PARADA, S. Kyun LIM, Qiren LIANG, Hua-yu WANG, Yufeng SHI
  • Prostate hyperplasia therapy
    Patent number: 7314911
    Abstract: The invention is a method for treating prostate hyperplasia by contacting a patient with insulin-6 in an amount effective to prevent or reduce prostate hyperplasia. The invention includes transgenic insulin-6 knockout mice that exhibit prostate hyperplasia and that can be used in screening agents for anti-prostate hyperplasia activity.
    Type: Grant
    Filed: August 17, 2004
    Date of Patent: January 1, 2008
    Assignee: Board of Regents, The University of Texas System
    Inventor: Luis F. Parada
  • Assay for pharmacological agents that block neurofibromin action
    Patent number: 6159680
    Abstract: A targeted disruption of the NF1 gene in mice has been used to demonstrate that both neural crest- and placode-derived sensory neurons isolated from NF1(-/-) embryos develop, extend neurites, and survive in the absence of neurotrophins, whereas their wild-type counterparts die rapidly unless NGF or BDNF is added to the culture medium. Moreover, NF1 mutant sympathetic neurons survive for extended periods and acquire mature morphology in the presence of NGF-blocking antibodies. The discovery is useful in screening candidate substances for inhibition of neurofibromin action and in therapy for neurodegeneration due to disease or trauma.
    Type: Grant
    Filed: July 7, 1995
    Date of Patent: December 12, 2000
    Assignee: Board of Regents, The University of Texas System
    Inventors: Luis F. Parada, Kristine S. Vogel
  • Nerve growth factor/receptor complex
    Patent number: 6071709
    Abstract: The present invention relates to a complex comprising nerve growth factor (NGF) and trk proto-oncogene protein and a complex comprising neurotrophic factors, NT-3 or BDNF, and trkB proto-oncogene protein. The present invention also relates to methods for detecting the presence of NGF, NT-3 or BDNF neurotrophic factors and trk and trk-related proto-oncogene receptors. The present invention further relates to methods that may be used in diagnostics and therapeutics for neurodegenerative diseases such as Alzheimer's and Huntington's by detecting complexes comprising NGF or NGF related neurotrophic factors bound to the product of the tyrosine kinase trk or related trk proto-oncogene family member.
    Type: Grant
    Filed: May 29, 1992
    Date of Patent: June 6, 2000
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Luis F. Parada, Dan Soppet, David Kaplan, Dionisio Martin-Zanca
  • Trk tyrosine kinase receptor is the physiological receptor for nerve growth factor
    Patent number: 5817471
    Abstract: The present invention relates to a complex comprising nerve growth factor (NGF) and trk-proto-oncogene protein. The present invention also relates to methods for detecting the presence of NGF and trk-proto-oncogene receptor. The present invention further relates to methods that can be used in diagnostics and therapeutics for neurodegenerative diseases such as Alzheimer's and Huntington's by detecting NGF-trk receptor pairs and the phosphorylation of trk protein.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 6, 1998
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: David R. Kaplan, Luis F. Parada
  • TRK tyrosine kinase receptor is the physiological receptor for nerve growth factor
    Patent number: 5811396
    Abstract: The present invention relates to a complex comprising nerve growth factor (NGF) and trk-proto-oncogene protein. The present invention also relates to methods for detecting the presence of NGF and trk-proto-oncogene receptor. The present invention further relates to methods that can be used in diagnostics and therapeutics for neurodegenerative diseases such as Alzheimer's and Huntington's by detecting NGF-trk receptor pairs and the phosphorylation of trk protein.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 22, 1998
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: David R. Kaplan, Luis F. Parada
  • TRK tyrosine kinase receptor is the physiological receptor for nerve growth factor
    Patent number: 5231001
    Abstract: The present invention relates to a complex comprising nerve growth factor (NGF) and trk-proto-oncogene protein. The present invention also relates to methods for detecting the presence of NGF and trk-proto-oncogene receptor. The present invention further relates to methods that may be used in diagnostics and therapeutics for neurodegenerative diseases such as Alzheimer's and Huntington's by detecting NGF-trk receptor pairs.
    Type: Grant
    Filed: March 14, 1991
    Date of Patent: July 27, 1993
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: David Kaplan, Dionisio Martin-Zanca, Luis F. Parada